SCHEMBL4609206

SCHEMBL4609206

Cc1cccc([C@H](CN2C(=O)c3ccccc3C2=O)NC2CCN(C(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.49
GPR119 Q8TDV5 2/20 0.48
EPHX2 P34913 1/20 0.45
MAPT P10636 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
TGFBR1 P36897 1/20 0.43
TP53 P04637 2/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4610073 0.91 BRD4 (0.51) BRD4GPR119MAPTL3MBTL1NPC1
SCHEMBL5576460 0.85 GPR119 (0.54) GPR119EPHX2MAPTL3MBTL1NPC1
SCHEMBL5576694 0.80 KMT2A (0.43) L3MBTL1NPC1ALDH1A1MAPK1HTT
SCHEMBL4610158 0.78 BRD4 (0.51) BRD4GPR119MAPTL3MBTL1NPC1
SCHEMBL4597819 0.76 GPR119 (0.53) GPR119EPHX2MAPTL3MBTL1NPC1
SCHEMBL23568961 0.75 GPR119 (0.57) BRD4GPR119L3MBTL1KDM4EPKM
SCHEMBL22849388 0.75 GPR119 (0.57) BRD4GPR119L3MBTL1KDM4EPKM
SCHEMBL22849387 0.75 GPR119 (0.57) BRD4GPR119L3MBTL1KDM4EPKM
SCHEMBL4597864 0.75 ALDH1A1 (0.55) GPR119MAPTL3MBTL1NPC1ALDH1A1
SCHEMBL6505071 0.75 ALDH1A1 (0.55) GPR119MAPTL3MBTL1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1924265-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS Genzyme Corporation (US) 2008-05-28 EP disclosed
US-20070066624-A1 Chemokine receptor binding compounds ANORMED, INC. (CA) 2007-03-22 US disclosed
WO-2007022371-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORPORATION (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066624-A1 Chemokine receptor binding compounds CCR5, CCR4, CCR1 BRD4 605/4885GPR119 229/4885EPHX2 2054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.